Cidara Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
Cidara Therapeutics has filed a definitive proxy statement related to its upcoming shareholder meeting.
Cidara Therapeutics is asking stockholders to vote on proposals including increasing authorized common stock and amending the 2024 Equity Incentive Plan at its upcoming annual meeting.
Cidara Therapeutics has filed a definitive proxy statement related to its upcoming shareholder meeting.
DEF 14A: Cidara Therapeutics Seeks Stockholder Approval for Key Proposals at Upcoming Annual Meeting
Cidara Therapeutics is asking stockholders to vote on several proposals at its annual meeting, including director elections, increasing authorized common stock, and approving a new equity incentive plan.
DEF 14A: Cidara Therapeutics Seeks Stockholder Approval for Reverse Stock Split to Regain Nasdaq Compliance
Cidara Therapeutics is asking stockholders to approve a reverse stock split and a reduction in authorized shares to meet Nasdaq's minimum bid price requirement and increase flexibility for future financing.